- Home
- KROS vs DSM Comparison
KROS vs DSM Comparison
Compare KROS & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KROS | DSM |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 256.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | DSM |
|---|---|---|
| Price | $11.04 | $5.55 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | 153.9K | ★ 247.7K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | ★ 146.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $5.07 |
| 52 Week High | $22.55 | $6.30 |
Technical Indicators
Market Signals| Indicator | KROS | DSM |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 63.19 |
| Support Level | $10.65 | N/A |
| Resistance Level | $11.69 | $6.21 |
| Average True Range (ATR) | 0.48 | 0.08 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 31.20 | 86.54 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.